Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.69 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.69 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.69 |
| ▸ | LTA4H | P09960 | 7/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225017 | 1.00 | PSMB1 (0.69) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL5685583 | 0.98 | PSMB1 (0.67) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL2249200 | 0.98 | LTA4H (0.68) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL491848 | 0.92 | HRH3 (0.69) | HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL5692315 | 0.91 | HRH3 (0.68) | HRH3KCNH2 | |
| SCHEMBL5856367 | 0.91 | HRH3 (0.68) | HRH3KCNH2 | |
| SCHEMBL30411052 | 0.91 | HRH3 (0.68) | HRH3KCNH2 | |
| SCHEMBL2005536 | 0.90 | HRH3 (0.67) | HRH3KCNH2KDM4E | |
| SCHEMBL8645630 | 0.90 | LTA4H (0.58) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL30410433 | 0.89 | HRH3 (0.67) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | claimed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | claimed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0954520-B1 | ISOFLAVONE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMA SPA (IT) | 2002-04-10 | — | — | EP | claimed |
| CN-108348605-B | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens | 帕拉卡林治疗公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11369618-B2 | Compounds, compositions and methods for prevention and/or treatment of cancer | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-06-28 | — | — | US | disclosed |
| CN-110526895-B | Preparation and separation method of raloxifene dimer | 重庆圣华曦药业股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3682880-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2020-02-04 | — | — | US | disclosed |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2020-02-04 | — | — | US | disclosed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0639567-A1 | INDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-22 | — | — | EP | disclosed |
| EP-0605524-A1 | ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN | SMITHKLINE BEECHAM PLC (GB) | 1994-07-13 | — | — | EP | disclosed |
| WO-1993006118-A1 | ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN | SMITHKLINE BEECHAM PLC (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0306827-B1 | AMIDE COMPOUNDS, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR ACTIVATING GASTRIC MOTOR FUNCTION CONTAINING THE SAME | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4983633-A | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0306827-A1 | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | SHBG, CYP19A1, AR | PSMB1 2987/4885PSMB5 3263/4885PSMB2 2612/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-11369618-B2 | Compounds, compositions and methods for prevention and/or treatment of cancer | GPER1, GPR3, GPR4 | PSMB1 2136/4885PSMB5 1891/4885PSMB2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.